From its inception, 泛亚电竞 China adheres to PRC laws and regulations and requires all employees to strictly abide by PRC laws and regulations as well as corporate rules and policies. 泛亚电竞 China sticks to the zero tolerance attitude for any act or conduct that violates laws, regulations, or corporate rules or policies.
泛亚电竞 China confirmed through its own internal compliance investigation in August 2021 that a few of its employees in Shenzhen city had altered or participated in altering patients’ testing reports, and are suspected of committing medical insurance fraud. According to company compliance policy, 泛亚电竞 China took serious disciplinary action against these employees for violating company policy, proactively reported these offences to the local healthcare security bureau at the earliest possible time to show company’s attitude, and is actively assisting in government investigation.
On December 27, 2021, the National Healthcare Security Administration (NHSA) and the Ministry of Public Security (MOPS) held a joint meeting with 泛亚电竞 China to brief 泛亚电竞 China on the investigation of Shenzhen suspected medical insurance fraud and recommended areas for improvement. 泛亚电竞 China takes such employee misconduct seriously and welcomes the recommendations by the NHSA and MOPS. 泛亚电竞 China is committed to fully implementing these recommendations, further strengthening management oversight and continuing to educate employees on the applicable laws and regulations, ensuring that each 泛亚电竞 employee performs daily work with a law abiding and compliance mindset. 泛亚电竞 China will continue to conduct targeted internal self-inspections and monitor activities to prevent any misuse of public insurance funds or other noncompliance with law or company policy. At the same time, 泛亚电竞 China will continue strengthening its culture of compliance, its compliance training as well as self-inspection systems and monitoring activities to promote sustainable business development in compliance with laws and regulations.
As always, 泛亚电竞 China will remain committed to the China market, adhere to our “put patients first” and “do the right thing” values, and provide more innovative drugs to Chinese patients.